Literature DB >> 31633764

Mutations that increase expression of the EmrAB-TolC efflux pump confer increased resistance to nitroxoline in Escherichia coli.

Fabiola Puértolas-Balint1, Omar Warsi1, Marius Linkevicius1,2, Po-Cheng Tang1,3, Dan I Andersson1.   

Abstract

OBJECTIVES: To determine the mechanism of resistance to the antibiotic nitroxoline in Escherichia coli.
METHODS: Spontaneous nitroxoline-resistant mutants were selected at different concentrations of nitroxoline. WGS and strain reconstruction were used to define the genetic basis for the resistance. The mechanistic basis of resistance was determined by quantitative PCR (qPCR) and by overexpression of target genes. Fitness costs of the resistance mutations and cross-resistance to other antibiotics were also determined.
RESULTS: Mutations in the transcriptional repressor emrR conferred low-level resistance to nitroxoline [nitroxoline MIC (MICNOX)=16 mg/L] by increasing the expression of the emrA and emrB genes of the EmrAB-TolC efflux pump. These resistant mutants showed no fitness reduction and displayed cross-resistance to nalidixic acid. Second-step mutants with higher-level resistance (MICNOX=32-64 mg/L) had mutations in the emrR gene, together with either a 50 kb amplification, a mutation in the gene marA, or an IS upstream of the lon gene. The latter mutations resulted in higher-level nitroxoline resistance due to increased expression of the tolC gene, which was confirmed by overexpressing tolC from an inducible plasmid in a low-level resistance mutant. Furthermore, the emrR mutations conferred a small increase in resistance to nitrofurantoin only when combined with an nfsAB double-knockout mutation. However, nitrofurantoin-resistant nfsAB mutants showed no cross-resistance to nitroxoline.
CONCLUSIONS: Mutations in different genes causing increased expression of the EmrAB-TolC pump lead to an increased resistance to nitroxoline. The structurally similar antibiotics nitroxoline and nitrofurantoin appear to have different modes of action and resistance mechanisms.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31633764     DOI: 10.1093/jac/dkz434

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Structure, Assembly, and Function of Tripartite Efflux and Type 1 Secretion Systems in Gram-Negative Bacteria.

Authors:  Ilyas Alav; Jessica Kobylka; Miriam S Kuth; Klaas M Pos; Martin Picard; Jessica M A Blair; Vassiliy N Bavro
Journal:  Chem Rev       Date:  2021-04-28       Impact factor: 60.622

2.  In vitro Activity of Repurposed Nitroxoline Against Clinically Isolated Mycobacteria Including Multidrug-Resistant Mycobacterium tuberculosis.

Authors:  Ada Marie Hoffmann; Martina Wolke; Jan Rybniker; Georg Plum; Frieder Fuchs
Journal:  Front Pharmacol       Date:  2022-05-26       Impact factor: 5.988

3.  TolCV1 Has Multifaceted Roles During Vibrio vulnificus Infection.

Authors:  Yue Gong; Rui Hong Guo; Joon Haeng Rhee; Young Ran Kim
Journal:  Front Cell Infect Microbiol       Date:  2021-04-30       Impact factor: 5.293

4.  Compared with Cotrimoxazole Nitroxoline Seems to Be a Better Option for the Treatment and Prophylaxis of Urinary Tract Infections Caused by Multidrug-Resistant Uropathogens: An In Vitro Study.

Authors:  Ulrich Dobrindt; Haleluya T Wami; Torsten Schmidt-Wieland; Daniela Bertsch; Klaus Oberdorfer; Herbert Hof
Journal:  Antibiotics (Basel)       Date:  2021-05-28

Review 5.  A How-To Guide for Mode of Action Analysis of Antimicrobial Peptides.

Authors:  Ann-Britt Schäfer; Michaela Wenzel
Journal:  Front Cell Infect Microbiol       Date:  2020-10-19       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.